Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD79: a review.

P G Chu1, D A Arber

  • 1Division of Pathology, City of Hope National Medical Center, Duarte, California 91010, USA.

Applied Immunohistochemistry & Molecular Morphology : AIMM
|June 9, 2001
PubMed
Summary
This summary is machine-generated.

CD79a and CD79b are key markers for identifying B-cell neoplasms and distinguishing them from other cancers. Their expression patterns offer diagnostic value throughout B-cell development and in specific B-cell malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.

Virchows Archiv : an international journal of pathology·2022
Same author

Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?

Best practice & research. Clinical haematology·2020
Same author

A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia.

International journal of laboratory hematology·2017
Same author

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia.

International journal of laboratory hematology·2017
Same author

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.

Leukemia·2015
Same author

The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia.

International journal of laboratory hematology·2015
Same journal

ISIMM Page.

Applied immunohistochemistry & molecular morphology : AIMM·2026
Same journal

Clinicopathologic Features of Warthin-Like Subtype of Papillary Thyroid Carcinoma.

Applied immunohistochemistry & molecular morphology : AIMM·2026
Same journal

HER2 In Situ Hybridization: Validation and Implementation of Brightfield Assay in a US Academic Pathology Laboratory.

Applied immunohistochemistry & molecular morphology : AIMM·2026
Same journal

Keratoameloblastoma of the Jaw Bones: Description of 2 Rare Cases and Cytokeratin Profile.

Applied immunohistochemistry & molecular morphology : AIMM·2026
Same journal

Role of Twist and Vimentin as Epithelial-Mesenchymal Transition Biomarkers in Oral Squamous Cell Carcinoma: Relation to Cancer-Associated Fibroblasts.

Applied immunohistochemistry & molecular morphology : AIMM·2026
Same journal

Exploring the Immune Microenvironment for Predicting Immunotherapy Efficacy in Epstein-Barr Virus-Associated Gastric Cancer.

Applied immunohistochemistry & molecular morphology : AIMM·2026
See all related articles

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • CD79, comprising CD79a and CD79b, is predominantly expressed on B cells and B-cell neoplasms.
  • Its expression ontogeny precedes immunoglobulin heavy-chain gene rearrangement and CD20 expression, and it persists later than CD20 during B-cell differentiation.

Purpose of the Study:

  • To review the molecular biology of CD79.
  • To evaluate the frequency and diagnostic utility of CD79 expression in B-cell neoplasms.

Main Methods:

  • Review of existing literature on CD79 expression and its role in B-cell neoplasms.
  • Analysis of diagnostic applications of CD79 antibodies in various hematologic malignancies.

Main Results:

  • CD79a and CD79b antibodies are valuable for differentiating B-cell neoplasms from T-cell or myeloid neoplasms.

Related Experiment Videos

  • These markers aid in distinguishing Hodgkin's lymphoma subtypes.
  • CD79 antibodies are crucial for diagnosing precursor B-acute lymphoblastic leukemia (pre-B-ALL), especially when other B-cell markers are negative.
  • CD79a serves as a primary B-cell marker when CD20 is lost or downregulated, as seen in diffuse large B-cell lymphoma or post-CD20 therapy.

    • Conclusions:

    • CD79a and CD79b are critical diagnostic markers in hematologic oncology.
    • Their unique expression patterns provide essential insights for diagnosing and classifying B-cell malignancies.